Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis

Dynamic Assessment of Cardiac Function in Acutely Decompensated Cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05413083

Acronym

DYNACORD-AD

Enrollment

Registered

2022-06-09

Start date

2022-06-06

Completion date

2024-10-31

Last updated

2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Liver Failure, Cardiomyopathies, Cirrhosis

Brief summary

This project aims to investigate cardiac function in patients with cirrhosis in the acute setting. Acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease progression and negative prognosis. Cardiocirculatory function will be assessed by serial assessments in patients admitted for acute decompensation of cirrhosis.

Detailed description

In this project we aim to investigate the dynamic role of cardiac function in the short-term evolution of patients with AD of cirrhosis through noninvasive and accessible tests and validate prognostic imaging and serum biomarkers. The main objectives are: 1. To describe changes and evolution of cardiac function in AD of cirrhosis 2. To investigate associations between echocardiographic parameters and serum biomarkers 3. To investigate the association between ACLF and cardiac dysfunction 4. To assess the short-term prognostic impact of cardiac function in AD and ACLF; 5. To evaluate the added predictive value of cardiac markers to current scores (CLIF-C).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* proven cirrhosis with acute decompensation

Exclusion criteria

* screening after \> 72 hours from admission * previous severe cardiac conditions (e.g. ischemic heart disease, atrial fibrillation, congestive heart failure, ICD) * concomitant severe disease (e.g. active neoplasia, severe COPD, etc) * lack of informed consent * intubated/ comatose patient

Design outcomes

Primary

Measure	Time frame	Description
cardiac dysfunction	90 days	rate of onset and evolution of systolic/ diastolic dysfunction in acute decompensation
composite outcome	90 days	risk of developing ACLF, disease worsening, or death during follow-up

Secondary

Measure	Time frame	Description
biomarkers	30 days	detecting biomarkers predictive for cardiac dysfunction and disease severity

Countries

Romania

Outcome results